Marksans Pharma has informed that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Oxybutynin hydrochloride 2.5mg/5ml Oral Solution from UK Medicines & Healthcare Products Regulatory Agency.
The above information is a part of company’s filings submitted to BSE.